Nippon India Mutual Fund trimmed its stake in Emcure Pharmaceuticals from 1.95% to 1.19%, selling 14,36,943 shares.
A global pharmaceutical manufacturer established in 1981, Emcure Pharmaceuticals produces and markets a comprehensive range of drug formulations across multiple therapeutic areas for domestic and international markets. The company operates manufacturing facilities that serve patients globally, focusing on both generic and specialty pharmaceutical products. Emcure's diversified operations and geographic presence establish it as a significant player in the pharmaceutical industry.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.
